Roche’s hunt for better eye disease gene therapy vectors has led to Avista Therapeutics. In a heavily backloaded deal, the Swiss Big Pharma has offered up $1 billion to secure the right to assess and ...
In recent years, we have seen rapid growth in the development of adeno-associated virus (AAV)-mediated gene therapy products that target fatal and highly debilitating diseases. Growth is evident in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results